Red herring prospectus

Instructure Files Registration Statement with SEC for an Initial Public Offering

Retrieved on: 
Monday, June 28, 2021

The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Key Points: 
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • The offering is subject to market conditions, and there can be no assurance as to whether, or when, the offering may be contemplated or as to the actual size or terms of the offering.
  • Instructure has applied to list its common stock on The New York Stock Exchange under the ticker symbol "INST."
  • A registration statement relating to these securities has been filed with the SEC but has not yet become effective.

North American Financial 15 Split Corp. Announces Successful Overnight Offering

Retrieved on: 
Friday, June 25, 2021

A prospectus supplement to the Companys short form base shelf prospectus dated July 3, 2020 containing important detailed information about the Preferred Shares and the Class A Shares being offered will be filed with securities commissions or similar authorities in all provinces of Canada.

Key Points: 
  • A prospectus supplement to the Companys short form base shelf prospectus dated July 3, 2020 containing important detailed information about the Preferred Shares and the Class A Shares being offered will be filed with securities commissions or similar authorities in all provinces of Canada.
  • Copies of the prospectus supplement and the short form base shelf prospectus may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the agents listed above.
  • There will not be any sale or any acceptance of an offer to buy the securities being offered until the prospectus supplement has been filed with the Securities Commissions or similar authorities in each of the provinces and territories of Canada.
  • For further information, please contact North American Financial 15 Split Corp. Investor Relations at 416-304-4443 Toll free at 1-877-4-Quadra (1-877-478-2372) or visit www.financial15.com .

Teknova Announces Pricing of its Upsized Initial Public Offering

Retrieved on: 
Friday, June 25, 2021

Additionally, Teknova has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Additionally, Teknova has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds of the offering, before deducting underwriting discounts and commissions and offering expenses payable by Teknova, are expected to be approximately $96.0 million, excluding any exercise of the underwriters option to purchase additional shares.
  • The offering is expected to close on or about June 29, 2021, subject to the satisfaction of customary closing conditions.
  • These statements include, but are not limited to, statements relating to the anticipated size of the initial public offering and the expected trading commencement and closing dates.

Synchronoss Technologies, Inc. Announces Proposed $100 Million Public Offering of Common Stock

Retrieved on: 
Thursday, June 24, 2021

Synchronoss also expects to grant the underwriters a 30-day option to purchase up to an additional $10 million of shares of common stock sold in the offering, at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • Synchronoss also expects to grant the underwriters a 30-day option to purchase up to an additional $10 million of shares of common stock sold in the offering, at the public offering price, less the underwriting discounts and commissions.
  • There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • B. Riley Securities, Inc. (BRS) is acting as the lead underwriter and sole book-running manager for the offering.
  • Concurrently with the offering, the Company is offering, by means of a separate prospectus supplement, $120 million aggregate principal amount of senior notes due 2026 (the Senior Notes).

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

Retrieved on: 
Thursday, June 24, 2021

The gross proceeds from the offering were approximately $50 million before deducting placement agent fees and other offering expenses.

Key Points: 
  • The gross proceeds from the offering were approximately $50 million before deducting placement agent fees and other offering expenses.
  • Anavex intends to use the net proceeds from the offering for advancing its pipeline and for working capital and general corporate purposes.
  • The shares of common stock described above were offered pursuant to Anavexs shelf registration statement on Form S-3 (File No.
  • A final prospectus supplement and the accompanying prospectus relating to the shares of common stock being offered in the registered direct offering were filed with the SEC.

DGAP-News: Cherry AG sets final offer price for its IPO at EUR 32 per share

Retrieved on: 
Wednesday, June 23, 2021

There will be no public offer of the securities in the United States.

Key Points: 
  • There will be no public offer of the securities in the United States.
  • It is not a prospectusor an offer to sell or a solicitation of an offer to buy securities.
  • However, the approval of the prospectus by BaFin should not be understood as an endorsement of the shares of Cherry AG.
  • In addition, copies of the prospectus are available free of charge from Cherry AG, Einsteinstrae 174, 81677 Munich, Germany.

Cyteir Therapeutics Announces Closing of Initial Public Offering

Retrieved on: 
Tuesday, June 22, 2021

Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share.

Key Points: 
  • Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share.
  • In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional 1,110,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
  • The gross proceeds to Cyteir from the offering were $133.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
  • This press release contains forward-looking statements regarding Cyteirs plans for its proposed initial public offering.

Anavex Life Sciences Announces $50 Million Registered Direct Offering

Retrieved on: 
Tuesday, June 22, 2021

The registered direct offering is expected to close on or about June 24, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The registered direct offering is expected to close on or about June 24, 2021, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering are expected to be approximately $50 million before deducting placement agent fees and other offering expenses.
  • Anavex currently intends to use the net proceeds from the offering for advancing its pipeline and for working capital and general corporate purposes.
  • A final prospectus supplement and the accompanying prospectus relating to the shares of common stock being offered in the registered direct offering will be filed with the SEC.

Martin Marietta Announces Pricing Terms of Debt Offering

Retrieved on: 
Monday, June 21, 2021

Martin Marietta has filed a shelf registration statement on Form S-3 (including a base prospectus) with the SEC for the offering to which this communication relates.

Key Points: 
  • Martin Marietta has filed a shelf registration statement on Form S-3 (including a base prospectus) with the SEC for the offering to which this communication relates.
  • Before you invest, you should read the prospectus in that registration statement and the prospectus supplement thereto and the other documents that Martin Marietta has filed or will file with the SEC for more complete information about Martin Marietta and this offering.
  • The offering will be made only pursuant to the terms of the relevant prospectus supplement (including the prospectus).
  • Martin Mariettas Magnesia Specialties business produces high-purity magnesia and dolomitic lime products used worldwide in environmental, industrial, agricultural and specialty applications.

Membership Collective Group Announces Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Monday, June 21, 2021

The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Key Points: 
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • A registration statement on Form S-1 relating to the proposed initial public offering has been filed with the SEC but has not yet become effective.
  • These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
  • The Membership Collective Group (MCG) is a global membership platform of physical and digital spaces that connects a vibrant, diverse and global group of members.